TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow

References

• Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis. 2013;8:231–238. doi:10.2147/COPD.S42866
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report); 2020. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed February 2, 2021.
   Google Scholar
• Lavorini F, Janson C, Braido F, et al. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13:1753466619884532. doi:10.1177/1753466619884532
   Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Alcázar B, et al. Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus. Pulm Pharmacol Ther. 2018;48:97–103. doi:10.1016/j.pupt.2017.10.006
   PubMed Web of Science ®Google Scholar
• Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461–472. doi:10.2147/TCRM.S160365
   PubMed Web of Science ®Google Scholar
• Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020;161:105857. doi:10.1016/j.rmed.2019.105857
   PubMed Web of Science ®Google Scholar
• Represas-Represas C, Aballe-Santos L, Fernández-García A, et al. Evaluation of suboptimal peak inspiratory flow in patients with stable COPD. J Clin Med. 2020;9:3949. doi:10.3390/jcm9123949
   PubMed Web of Science ®Google Scholar
• Ghosh S, Pleasants RA, Ohar JA, et al. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:585–595. doi:10.2147/COPD.S195438
   PubMed Web of Science ®Google Scholar
• Loh CH, Peters SP, Lovings TM, et al. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305–1311. doi:10.1513/AnnalsATS.201611-903OC
   PubMed Web of Science ®Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.1416
   PubMed Web of Science ®Google Scholar
• Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–19. doi:10.1016/j.rmed.2007.07.031
   PubMed Web of Science ®Google Scholar
• Capstick TG, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med. 2012;6(1):91–101. doi:10.1586/ers.11.89
   PubMed Web of Science ®Google Scholar
• Newman SP. Inhaler treatment options in COPD. Eur Respir Rev. 2005;14(96):102–108. doi:10.1183/09059180.05.00009605
   Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14:1103–1107.
   PubMed Web of Science ®Google Scholar
• Duarte AG, Tung L, Zhang W, et al. Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. Chronic Obstr Pulm Dis. 2019;6:246–255.
   PubMed Web of Science ®Google Scholar
• Dhand R, Eicher J, Hansel M, et al. Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. Int J Chron Obstruct Pulmon Dis. 2019;14:509–523. doi:10.2147/COPD.S190639
   PubMed Web of Science ®Google Scholar
• Hochrainer D, Holz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273–282. doi:10.1089/jam.2005.18.273
   PubMedGoogle Scholar
• Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat® inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:1565–1577. doi:10.2147/COPD.S115886
   PubMed Web of Science ®Google Scholar
• Pitcairn G, Reader S, Pavia D, et al. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ inhaler compared to deposition by metered dose inhaler or by turbuhaler dry powder inhaler. J Aerosol Med. 2005;18(3):264–272. doi:10.1089/jam.2005.18.264
   PubMedGoogle Scholar
• Brand P, Hederer B, Austen G, et al. Higher lung deposition with Respimat® Soft Mist™ inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3:763–770. doi:10.2147/COPD.S3930
   PubMedGoogle Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.00136014
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Limited. Spiolto Respimat 2.5 microgram/2.5 microgram, inhalation solution – summary of product characteristics; 2017. Available from: https://www.medicines.org.uk/emc/medicine/30495. Accessed November 6, 2019.
   Google Scholar
• Ferguson GT, Karpel J, Bennett N, et al. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017;27(1):7. doi:10.1038/s41533-016-0002-x
   PubMedGoogle Scholar
• Boehringer Ingelheim. New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries; 2015. Available from: https://www.boehringer-ingelheim.com/press-release/new-advance-copd-maintenance-treatment-spiolto-respimat-approved-first-european. Accessed February 2, 2021.
   Google Scholar
• Buhl R, Singh D, de la Hoz A, et al. Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of the TONADO® and OTEMTO® studies. Adv Ther. 2020;37(8):3485–3499. doi:10.1007/s12325-020-01373-3
   PubMed Web of Science ®Google Scholar
• Buhl R, de la Hoz A, Xue W, et al. Efficacy of tiotropium/olodaterol compared with tiotropium as a first-line maintenance treatment in patients with COPD who are naïve to LAMA, LABA and ICS: pooled analysis of four clinical trials. Adv Ther. 2020;37(10):4175–4189. doi:10.1007/s12325-020-01411-0
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Buhl R, Singh D, et al. Tiotropium/olodaterol decreases exacerbation rates compared with tiotropium in a range of patients with COPD: pooled analysis of the TONADO®/DYNAGITO® trials. Adv Ther. 2020;37(10):4266–4279. doi:10.1007/s12325-020-01438-3
   PubMed Web of Science ®Google Scholar
• Ciciliani AM, Denny M, Langguth P, et al. Lung deposition using the Respimat® Soft Mist™ inhaler mono and fixed-dose combination therapies: an in vitro/ in silico analysis. COPD. 2021;18(1):91–100. doi:10.1080/15412555.2020.1853091
   PubMedGoogle Scholar
• Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145–155.
   PubMedGoogle Scholar
• Price DB, Yang S, Ming SWY, et al. Physiological predictors of peak inspiRatory flow using observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2018;13:3937–3946. doi:10.2147/COPD.S174371
   PubMed Web of Science ®Google Scholar
• Altman P, Wehbe L, Dederichs J, et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med. 2018;18(1):100. doi:10.1186/s12890-018-0662-0
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ohar JA, Barnes CN, et al. Nebulized versus dry powder long-acting muscarinic antagonist bronchodilators in patients with COPD and suboptimal peak inspiratory flow rate. Chronic Obstr Pulm Dis. 2019;6:321–331.
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333–1343. doi:10.1164/rccm.201604-0733OC
   PubMed Web of Science ®Google Scholar
• Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31(1):78. doi:10.1183/09031936.00024807
   PubMed Web of Science ®Google Scholar